Eyewire Today http://eyewiretoday.com/ Eyewire Today en-us Mon, 26 Jun 2017 17:13:35 GMT Mon, 26 Jun 2017 17:13:35 GMT EyewireToday.com Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment http://eyewiretoday.com/view.asp?url=phase-3-results-published-for-investigational-levodopa-induced-dyskinesia-treatment Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD... Wed, 14 Jun 2017 04:00:00 GMT AHS 2017: Amgen’s CGRP Inhibitor Reduces Migraine Days http://eyewiretoday.com/view.asp?url=amgen-unveils-positive-phase-2-data-for-cgrp-inhibitor New Phase 2 data show that Amgen’s investigational investigational CGRP inhibitor erenumab is effective at preventing migraine in patients experiencing 15 or more migraine days per month. In a study presented at the recent American Headache Soc... Tue, 13 Jun 2017 04:00:00 GMT Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT http://eyewiretoday.com/view.asp?url=anti-alpha-synuclein-antibody-shows-early-potential-as-parkinsons-dmt PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), according to a study presented at the recent International Congress of Parkinso... Fri, 9 Jun 2017 04:00:00 GMT AHS 2017 Meeting: Non-Invasive Medical Devices Show Promise for Severe Headaches http://eyewiretoday.com/view.asp?url=ahs-2017-meeting-non-invasive-medical-devices-show-promise-for-severe-headaches Results from studies presented at the American Headache Society Annual Meeting in Boston suggest that non-invasive medical devices offer effective interventions for individuals with migraine.New findings from a randomized, placebo-controlled study sh... Thu, 8 Jun 2017 04:00:00 GMT AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine http://eyewiretoday.com/view.asp?url=ahs-2017-meeting-prochlorperazine-more-effective-than-the-opioid-hydromorphone-for-acute-migraine A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazine is more effective than the opioid drug, hydromor... Thu, 8 Jun 2017 04:00:00 GMT Smartphone Sensor Data Offer Insights Into Daily Functioning in Patients with Parkinson’s Disease http://eyewiretoday.com/view.asp?url=smartphone-sensor-data-offer-insights-into-daily-functioning-in-patients-with-parkinsons-disease Smartphones are a valuable resource in gaining mobility data in patients with Parkinson’s disease, according to new research presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders (Abstract 541). Evalua... Wed, 7 Jun 2017 04:00:00 GMT Teva’s Fremanezumab Reduces Monthly Headache Days in Phase 3 Chronic Migraine Study http://eyewiretoday.com/view.asp?url=tevas-fremanezumab-reduces-monthly-headache-days-in-phase-3-chronic-migraine-study Results from the Phase 3 HALO study suggest that fremanezumab (Teva Pharmaceuticals) reduces the number of monthly headache days in patients with chronic migraine. Fremanezumab is a fully-humanized monoclonal antibody targeting the CGRP ligand. In t... Thu, 1 Jun 2017 04:00:00 GMT Neurodegenerative Diseases Linked by Abnormal Proteins Causing Similar Damage to Brain Cells http://eyewiretoday.com/view.asp?url=neurodegenerative-diseases-linked-by-abnormal-proteins-causing-similar-damage-to-brain-cells Abnormal proteins found in Alzheimer's disease, Parkinson's disease, and Huntington's disease share a similar ability to cause damage when they invade brain cells, according to recently published findings (Acta Neuropathol, May 19, 2017).... Tue, 30 May 2017 04:00:00 GMT NEJM Publishes Phase 3 Data for Epidiolex in Dravet Syndrome as Manufacturer Eyes Mid-2017 NDA Submission http://eyewiretoday.com/view.asp?url=nejm-publishes-phase-3-data-for-epidiolex-in-dravet-syndrome-as-manufacturer-eyes-mid-2017-nda-submission The New England Journal of Medicine has published results from a Phase 3 study showing that Epidiolex (cannabidiol, GW Pharmaceuticals) reduces monthly convulsive seizure frequency compared to placebo in children with Dravet syndrome. The study rando... Fri, 26 May 2017 04:00:00 GMT Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial http://eyewiretoday.com/view.asp?url=celgenes-investigational-ms-agent-reduces-annual-relapse-rate-but-falls-short-of-disability-endpoint-in-phase-3-trial New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way but does not significantly impact disease disability. In the RADIANCE tria... Tue, 23 May 2017 04:00:00 GMT Migraine Prevalence Higher in Collegiate Athletes, New Study Finds http://eyewiretoday.com/view.asp?url=migraine-prevalence-higher-in-collegiate-athletes-new-study-finds New findings suggest that collegiate athletes have an increased prevalence of migraines, with female athletes being particularly affected. In a retrospective cross-section survey, researchers evaluated 834 student athletes from NCAA Division-I instit... Fri, 19 May 2017 04:00:00 GMT Lilly’s Investigational Monoclonal Antibody for Migraine Scores Positive Phase 3 Results http://eyewiretoday.com/view.asp?url=lillys-investigational-monoclonal-antibody-for-migraine-scores-positive-phase-3-results New Phase 3 data suggest that Eli Lilly’s investigational monoclonal antibody galcanezumab may significantly reduce the number of monthly migraine headache days. In the EVOLVE-1 study, patients with episodic migraine treated with galcanezumab 1... Fri, 12 May 2017 04:00:00 GMT Elevated B2M Levels Tied to Ischemic Stroke Risk in Women http://eyewiretoday.com/view.asp?url=elevated-b2m-levels-tied-to-ischemic-stroke-risk-in-women β2-microglobulin (B2M) levels may be an indicator of ischemic stroke risk in women, according to new findings published in Neurology (May 10). Investigators performed a nested case-control study among women enrolled in the Nurses' Health Stu... Fri, 12 May 2017 04:00:00 GMT MS Topography App Launches http://eyewiretoday.com/view.asp?url=ms-topography-app-now-available A new app that offers a new, visual way of understanding multiple sclerosis (MS) was recently launched at the American Academy of Neurology Annual Meeting in Boston. The app is a disease simulation that creates visualization of MS as a swimming pool.... Thu, 4 May 2017 04:00:00 GMT New Data Highlight Efficacy and Safety of Brain Responsive Neuromodulation for Reduction of Seizures http://eyewiretoday.com/view.asp?url=seven-year-data-highlight-efficacy-and-safety-of-brain-responsive-neuromodulation-for-reduction-of-seizures Two new studies offer long-term perspective on the efficacy and safety of brain responsive neuromodulation for the reduction of seizures. One study evaluated the effects of NeuroPace’s RNS System in patients with medically intractable mesial te... Wed, 3 May 2017 04:00:00 GMT AAN 2017 Meeting: Racial and Regional Disparities Identified in Endovascular Care Delivery http://eyewiretoday.com/view.asp?url=aan-2017-meeting-racial-and-regional-disparities-identified-endovascular-care-delivery Access to endovascular care is significantly impacted by factors such as race, region, and hospital, according to findings presented this week at the American Academy of Neurology (AAN) Annual Meeting in Boston. Investigators analyzed data from a lar... Fri, 28 Apr 2017 04:00:00 GMT AAN 2017 Meeting: New Evidence Suggest Parkinson’s Originates in the Gut http://eyewiretoday.com/view.asp?url=aan-2017-meeting-new-evidence-suggest-parkinsons-originates-in-the-gut Parkinson’s disease may start in the gut and spread to the brain via the vagus nerve, according to a study published in the April 26, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology. When researche... Wed, 26 Apr 2017 04:00:00 GMT AAN 2017 Meeting: New Data Reinforce Efficacy of Ocrelizumab http://eyewiretoday.com/view.asp?url=aan-2017-new-data-reinforce-efficacy-of-ocrelizumab New data presented at the American Academy of Neurology (AAN) Annual Meeting in Boston show the benefits of ocrelizumab in relapsing multiple sclerosis (MS). In a pooled analysis of Phase 3 OPERA studies, ocrelizumab reduced the relapse rate by 55 pe... Wed, 26 Apr 2017 04:00:00 GMT AAN Unveils New Guideline for SUDEP at Annual Meeting http://eyewiretoday.com/view.asp?url=aan-unveils-new-guideline-for-sudep-at-annual-meeting The American Academy of Neurology (AAN) and the American Epilepsy Society (AES) have released a new joint guideline for sudden unexpected death in epilepsy (SUDEP) at the AAN Annual Meeting in Boston. SUDEP is rare in children, affecting just one in ... Tue, 25 Apr 2017 04:00:00 GMT Elekta: New Data on Stereotactic Neurosurgery Devices Presented at AANS http://eyewiretoday.com/view.asp?url=elekta-new-data-on-stereotactic-neurosurgery-devices-presented-at-aans Elekta's Leksell Gamma Knife® radiosurgery system has been highlighted in more than 15 scientific presentations at the American Association of Neurological Surgeons (AANS) Annual Meeting in Los Angeles, the company reports. "Stereotactic... Mon, 24 Apr 2017 04:00:00 GMT Stroke Hospitalization Rates and Risk Factors Increasing in Young Adults http://eyewiretoday.com/view.asp?url=stroke-hospitalization-rates-and-risk-factors-increasing-in-young-adults Rates of acute ischemic stroke are increasing in young adults, new findings suggest (JAMA Neurology, April 10). Investigators analyzed stroke hospitalization rates as well as associated risk factors among patients between the ages of 18 and 64 years ... Mon, 17 Apr 2017 04:00:00 GMT New Evidence Suggests Potential for Blood-Based Alzheimer’s Biomarker http://eyewiretoday.com/view.asp?url=new-evidence-suggests-potential-for-blood-based-alzheimers-biomarker Plasma neurofilament light (NFL) may represent a blood-based, non-invasive biomarker in Alzheimer’s disease (AD), according to new findings published in the JAMA Neurology (March 27, 2017). In a prospective case-control study, investigators use... Tue, 28 Mar 2017 04:00:00 GMT Review Identifies Antidepressants and AEDs Effective for Nerve Pain http://eyewiretoday.com/view.asp?url=review-identifies-antidepressants-and-aeds-effective-for-nerve-pain A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain. In findings published in the journal Neurology, researchers found moderate evidence in studies and syst... Fri, 24 Mar 2017 04:00:00 GMT ISC 2017: Exercise Significantly Improves Cognitive Impairment After Stroke http://eyewiretoday.com/view.asp?url=isc-2017-exercise-significantly-improves-cognitive-impairment-after-stroke New research presented at the ongoing International Stroke Conference 2017 suggests that structured exercise training can significantly improve brain function in stroke survivors. Given the prevalence of cognitive impairments after stroke, researcher... Thu, 23 Feb 2017 04:00:00 GMT ISC 2017: Integrative Aspiration System Compares Favorably to Stent Retrievers as Frontline Thrombectomy Therapy for Acute Stroke http://eyewiretoday.com/view.asp?url=isc-2017-integrative-aspiration-system-compares-favorably-to-stent-retrievers-as-frontline-thrombectomy-therapy-for-acute-stroke New research presented at the ongoing International Stroke Conference in Houston suggests that the ADAPT (A Direct Aspiration, First Pass Technique) compares favorably to the use of stent retrievers as an effective frontline thrombectomy approach. Da... Thu, 23 Feb 2017 04:00:00 GMT